BIRC5 and prostate carcinoma: This indicats that tissues from non-tumor prostate tissues, primary and metastatic stage prostate cancer tissues dataset, with down-regulated KRAS signatures, have more TCF7 and BIRC5 expression (Supplementary Figures S3A and S3B).